CRs have also been reported in patients with SS together with patients with PTL, unspecified, and CD30+ ALCL.48–50 Finally, panobinostat has demonstrated a response rate of six out of 10 patients with advanced-stage CTCL patients, with two CRs and four PRs.51 Although objective responses, i.e. complete or partial, are not reached by all CTCL patients, many still benefit from treatment by achieving stable disease and/or pruritus relief.45–47. The gene discussed is TNFRSF8; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.